Therapeutic agents for the treatment of lymphoid malignancies

US8318812B2 · kind B2 · utility

Assignee

• The Ohio State University Research Foundation · US

Inventors

• John C. Byrd · Columbus, US
• Danilo Perrotti · Dublin, US
• Ching-Shih Chen · Taipei, TW
• James T. Dalton · Columbus, US
• Frank Frissora · Columbus, US
• Xiaobin Zhao · Edinburgh, GB
• Qing Liu · Gungahlin, AU
• Natarajan Muthusamy · Galloway, US

Key dates

• Filing date: Jun 1, 2007
• Grant date: Nov 27, 2012
• Expiry date: Oct 3, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.